以雷贝拉唑与加替沙星为基础的三联疗法作为幽门螺杆菌感染根除失败的补救方案的研究  

The study of rabeprazole and gatifloxacin-based triple therapies after Helicobacter pylori eradication failure

作　　者：钟英强[1] 郭佳念[1] 许哲[1] 颜蓉[1] 李惠君[1] 曾志勇[1] 

机构地区：[1]中山大学附属第二医院消化内科,广州510120

出　　处：《中国新药杂志》2007年第13期1046-1049,共4页Chinese Journal of New Drugs

基　　金：中国杨森科学委员会基金资助项目(JRC01)

摘　　要：目的:研究以雷贝拉唑和加替沙星为基础的三联疗法作为幽门螺杆菌(HP)感染根除2次以上均失败的补救方案的价值。方法:以雷贝拉唑、加替沙星和进口克拉霉素组成方案,分为7 d疗程组(A组)和14 d疗程组(B组)。60例HP感染根除失败患者随机分为A和B组进行前瞻性研究,应用药物经济学分析两组的C/E比。结果:HP的根除方案的应用仍很不规范。A和B组的根除率分别为75.0%和93.3%(P<0.05)。A和B组的不良反应发生率分别为17.9%和23.3%(P>0.05)。A和B组的C/E比分别为7.44和11.96。结论:以雷贝拉唑、加替沙星为基础的三联疗法作为HP根除失败的补救方案有较高的根除率。Objective： To investigate the effect of rabeprazole and gatifloxacin-based triple therapies after Helicobacter pylori（HP）eradication failure more than 2 times. Methods： The regimens consisted of rabeprazole, gatifloxacin and clarithromycin. Sixty patients with HP eradication failure were randomized into the group A （ for 7 days） and B （ for 14 days）. The cost-effect ratio （C/E） were analysed. Results： The eradication regimens performance was not standarded. The eradication rates of group A and B were 75.0% and 93.3% respectively（P 〈0.05）. The adverse event rates of group A and B were 17.9% and 23.3% respectively（P 〉 0.05）. The cost-effect ratios of group A and B were 7.44 and 11.96, respectively. Conclusions： The eradication rate of rabeprazole and gatifloxacin-based triple therapies of HP eradication failure is relatively high.

关 键 词：雷贝拉唑 加替沙星 幽门螺杆菌 药物治疗 不良反应 疗效-费用 

分 类 号：R975.2[医药卫生—药品] R571[医药卫生—药学]